Nanosonics Limited · ASX:NAN
Nanosonics — Shareholder Meeting (November 2024)
38 slides from Nanosonics's shareholder meeting presentation, Nov 12, 2024
Slide 1: Welcome to the 2024 Annual General Meeting
For personal use only Nanosonics Limited Welcome to the 2024 Building A, Level 1, 11 Talavera Road Annual General Meeting Macquarie Park 12 November 2024 NSW 2113 Australia
Slide 2: Board of Directors
For personal use only Steve Sargent Michael Kavanagh Lisa McIntyre David Fisher Non-Executive Director CEO, President and Non-Executive Director Non-Executive Director and Chairman Managing Director Tracey Batten Marie McDonald Geoff Wilson Larry Marshall Non-Executive Director Non-Executive Directo
Slide 3: How to ask a question
• To ask a written question select the Q & A icon For personal use only • Select the topic your question relates to from the drop-down list • Type your question in the text box and press the send button • To ask a verbal question follow the instructions below the broadcast window. Nanosonics Limited
Slide 4: How to vote
•When the poll is open, select the vote icon at For personal use only the top of the screen •To vote, select either For, Against or Abstain •You will see a vote confirmation •To change or cancel your vote “click here to change your vote” at any time until the poll is closed Nanosonics Limited | Annu
Slide 5: 2024 Annual General Meeting Chairman's Address
For personal use only 2024 Annual General Meeting Chairman’s Address Steven Sargent Non-executive Director and Chairman
Slide 6: Growth in ultrasound and endoscopy, healthcare acquired infections, digitisation
For personal use only GROWTH IN ULTRASOUND HEALTHCARE ACQUIRED DIGITISATION & AUTOMATION & ENDOSCOPY GENERALLY INFECTIONS The digital world is permeating Both ultrasound and endoscope The negative impacts on patients all aspects of healthcare; modalities remain as relevant as and healthcare systems
Slide 7: Leading ultrasound reprocessing and transforming endoscope reprocessing
We continue to lead the Ultrasound Reprocessing We anticipate that CORIS will transform the For personal use only market through our trophon2 technology Endoscope Reprocessing market Nanosonics Limited | Annual General Meeting 2024 | 7
Slide 8: Key FY25 Targets
Key FY25 Targets For personal use only 100% renewable electricity for Australian and United States (circa 100% of scope 1&2). Work with transport providers on reducing scope 3 emissions Conduct onsite modern slavery audits in conjunction with quality audits with tier one suppliers Continue g
Slide 9: Board of Directors
For personal use only Steve Sargent Michael Kavanagh Lisa McIntyre David Fisher Non-Executive Director CEO, President and Non-Executive Director Non-Executive Director and Chairman Managing Director Tracey Batten Marie McDonald Geoff Wilson Larry Marshall Non-Executive Director Non-Executive Directo
Slide 10: 2024 Annual General Meeting CEO Address
For personal use only 2024 Annual General Meeting CEO Address Michael Kavanagh CEO and President
Slide 11: FY24 Key highlights
FY24 Key highlights Revenue • Total revenue: $170.0 million, up 2% on prior period (0% in constant currency1) • H2 revenue: $90.4 million, up 14% on FY24 H1 For personal use only Global installed base • Up 2,340 units to 34,790 units globally, a 7% increase in the last 12 months trophon®2 upgrades •
Slide 12: Business outlook for FY25
Business outlook for FY25 The Company is optimistic about the potential for growth in the trophon ultrasound reprocessing sector and its wider strategic objectives for expansion, particularly For personal use only regarding the prospects with CORIS following regulatory approval. • Growing capital re
Slide 13: Our Mission
Our Mission We improve the safety of patients, clinics, their staff and the environment by For personal use only transforming the way infection prevention practices are understood and conducted and introducing innovative technologies that deliver improved standards of care. Our Aspiration Transform
Slide 14: Our aspiration and strategy
Our aspiration and strategy Transform medical device reprocessing for improved patient safety and better health outcomes For personal use only By establishing new standards of care and category leadership Leading ultrasound reprocessing Transforming endoscope reprocessing R&D, strategic partnerships
Slide 15: Significant global opportunity
Significant global opportunity A GLOBAL INSTALLED BASE OPPORTUNITY OF 25% market 140,000 UNITS For personal use only 1 penetration NORTH AMERICA EUROPE AND MIDDLE EAST ASIA PACIFIC Installed Base Opportunity Market Penetration Installed Base Opportunity Market Penetration Installed Base Opportunity
Slide 16: Ongoing NA market opportunity
Ongoing NA market opportunity Approximately 270,000 ultrasound devices in use in North America across…. For personal use only 5,700 relevant hospitals with departments using ultrasound1 trophon TAM NORTH AMERICA2 60,000 units trophon devices established as standard of care with 50% market penetratio
Slide 17: trophon growth and value opportunity
trophon growth and value opportunity We strive to deliver continuous value over the lifetime of trophon devices by driving improved compliance with HLD standards and owning the ultrasound reprocessing value chain through eco-system & digital offerings. For personal use only Initial installation Upgr
Slide 18: Europe fundamentals improving
Europe fundamentals improving EUROPE AND MIDDLE EAST Market Penetration For personal use only Installed Base Opportunity 1 40,000 1 5% UNITS UK 25% Strengthening Fundamentals • Direct in markets with strongest fundamentals • Strategic partnership with Eco Lab in France and ME • Expanded offerings to
Slide 19: Japan fundamentals improving
Japan fundamentals improving Japan Market Development Progressing ASIA PACIFIC • Japanese Society of Sonographer (JSS) has published a new guideline recommending Spaulding For personal use only Installed Base Opportunity Market Penetration 1 classification based HLD practice for ultrasound trnasduce
Slide 20: Leading Ultrasound Reprocessing: Significant ongoing growth opportunity
Leading For personal use only Ultrasound Reprocessing Significant ongoing growth opportunity Nanosonics Limited | Annual General Meeting 2024 | 20
Slide 21: Transforming endoscope reprocessing
For personal use only Transforming endoscope reprocessing Nanosonics Limited | Annual General Meeting 2024 | 21
Slide 22: Adverse event reports for endoscopes continue to grow
Adverse event reports for endoscopes continue to grow Adverse events continue to grow and Numerous outbreaks caused by multi-drug resistant For personal use only reprocessing failures and infections have been organisms continue to occur, with significant impact reported across all major endoscope ty
Slide 23: CORIS
CORIS CORIS aims to deliver safer endoscopes to patients through superior cleaning For personal use only Combining a unique mode of action with the Designed to deliver CORIS QUANTUM cleaning agent that can remove better cleaning even the toughest biofilm from all channels, even outcomes the smallest
Slide 24: Evidence of biofilm formation in endoscope channels
Evidence of biofilm formation in endoscope channels Published data: Biofilm found in clinical lumens1 For personal use only • Study withdrew clinically used gastroscopes, replaced lumens, then returned the scopes to clinical use. • At 30- and 60-day timepoints the lumens were recovered and sent for
Slide 25: CORIS delivers cleaning results far exceeding manual cleaning
CORIS delivers cleaning results far exceeding manual cleaning Key findings For personal use only • CORIS significantly outperformed manual cleaning in all channels across all markers including protein, total organic carbon and viable bacteria. • 1.4-mm and 3.7-mm channels were tested, representing a
Slide 26: Large global opportunity for CORIS
Large global opportunity for CORIS More than 60 million flexible procedures annually across major markets For personal use only Endoscopy, 60 million annual procedures1 Manual cleaning costs2 EXAMPLE: Total cost to manually clean a single GI endoscope2 USA Germany $37 France Total cost Spain/Italy r
Slide 27: CORIS - the pathway to market
CORIS - the pathway to market1 For personal use only United States De Novo Regulatory Pathway Food and As CORIS is a completely novel technology platform, Drug Nanosonics is pursuing the FDA’s De Novo regulatory pathway in the United States. Approval via this pathway would establish Administration C
Slide 28: Resolutions
For personal use only Resolutions 2024 Annual General Meeting
Slide 29: Re-election of a Director Ms Marie McDonald
Re-election of a Director Ms Marie McDonald For personal use only To consider and, if thought Proxy votes received Number % fit, to pass the following For : 196,046,026 98.90 ordinary Resolution: Against : 1,966,997 0.99 Discretion : 219,019 0.11 That Ms Marie McDonald, Abstained/Excluded : 124,831
Slide 30: Remuneration Report
Remuneration Report For personal use only To consider and, if thought fit, Proxy votes received Number % to pass the following ordinary For : 196,343,254 99.38 Resolution: Against : 1,006,254 0.51 Discretion : 224,559 0.11 Abstained/Excluded : 109,446 - That the Remuneration Report for the financial
Slide 31: Issue of Service Rights to the CEO (2024 STI)
Issue of 21,914 Service Rights to the Chief Executive Officer and President, Mr Michael Kavanagh, in respect of Mr Kavanagh’s 2024 Short Term Incentive grant (2024 STI) under the Nanosonics Equity Plan For personal use only To consider and, if thought fit, to pass the following Proxy votes received
Slide 32: Issue of Performance Rights to the CEO (2024 LTI)
Issue of 470,877 Performance Rights to the Chief Executive Officer and President, Mr Michael Kavanagh, in respect of Mr Kavanagh’s 2024 Long-Term Incentive grant (2024 LTI) under the Nanosonics Equity Plan For personal use only To consider and, if thought fit, to pass the Proxy votes received Number
Slide 33: Re-insertion of Proportional Takeover Provisions in Constitution
Re-insertion of Proportional Takeover Provisions in Constitution For personal use only To consider and, if thought fit, to pass the Proxy votes received Number % following special Resolution: For : 197,795,082 99.83 Against : 111,760 0.06 That the proportional takeover provisions in Discretion : 223
Slide 34: How to ask a question
• To ask a written question select the Q & A icon For personal use only • Select the topic your question relates to from the drop-down list • Type your question in the text box and press the send button • To ask a verbal question follow the instructions below the broadcast window. Nanosonics Limited
Slide 35: How to vote
•When the poll is open, select the vote icon at For personal use only the top of the screen •To vote, select either For, Against or Abstain •You will see a vote confirmation •To change or cancel your vote “click here to change your vote” at any time until the poll is closed Nanosonics Limited | Annu
Slide 36: How to ask a question
• To ask a written question select the Q & A icon For personal use only • Select the topic your question relates to from the drop-down list • Type your question in the text box and press the send button • To ask a verbal question follow the instructions below the broadcast window. Nanosonics Limited
Slide 37: Disclaimer
• This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other ne
Slide 38: Nanosonics Limited contact details
For personal use only Nanosonics Limited Building A Level 1 11 Talavera Road Macquarie Park NSW 2113 Australia T +61 2 8063 1600 E info@nanosonics.com.au www.nanosonics.com.au ABN 11 095 076 896 Nanosonics Limited | Annual General Meeting 2024 | 38